Reports
Sale
Asia Pacific Respiratory Inhalers Market Size, Share, Growth: By Product Type: Dry Powdered Inhalers, Metered Dose Inhalers, Nebulizers, Others; By Technology: Manually Operated Inhaler, Digitally Operated Inhaler; By Indication; By Distribution Channel; By End User; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Asia Pacific Respiratory Inhalers Market Outlook
The global respiratory inhalers market size was valued at USD 33.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. It is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to attain USD 53.9 billion by 2032.
Key Takeaways
- Recent data reveals that China accounts for nearly 25% of all COPD cases globally, with around 100 million living with this chronic lung condition . The rising burden of respiratory conditions is expected to fuel market demand.
- In August 2023, AstraZeneca revealed its plan to invest an additional amount of USD 250 million in its asthma inhaler plant in China’s Qingdao, with the total investment in the factory reported to be USD 700 million. Such substantial investments to address the medical needs of the rising patient pool are expected to elevate the Asia Pacific respiratory inhalers market value.
- The market is also influenced by the increased initiatives and campaigns to raise awareness about respiratory diseases and their management. In May 2023, Alkem Laboratories Limited announced its 'Reliever Free India' initiative to raise awareness about asthma and the hazards of over-usage of reliever medication.
Asia Pacific Respiratory Inhalers Market Analysis
Respiratory inhalers are medical devices that are employed to deliver medication directly to the lungs of patients suffering from respiratory disorders. There is a growing trend towards the adoption of digitally operated and smart inhaler technologies in the market. Smart inhalers are known to facilitate effective disease management by monitoring and providing feedback on the patient's usage patterns. Thus, the Asia Pacific respiratory inhalers market growth is significantly influenced by the technological advancements in inhaler devices.
The market is also impacted by the rising burden of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension in the Asia Pacific region. Recent data reveals that China accounts for nearly 25% of all COPD cases globally, with around 100 million living with this chronic lung condition . Moreover, it is estimated that with the rising smoking rates and an aging population, the prevalence rate of COPD is likely to increase in the coming 40 years. Consequently, the market demand for respiratory inhalers is poised to witness a surge in the forecast period.
One of the major Asia Pacific respiratory inhalers market trends is the increased investment in the respiratory inhaler segment by key market players with the aim to improve access to innovative drugs and accommodate the growing healthcare demands. In August 2023, AstraZeneca announced its plan to invest an additional amount of USD 250 million in its asthma inhaler plant in China’s Qingdao, with the total investment in the factory reported to be USD 700 million. By collaborating with the Qingdao municipal government, the firm intends to manufacture its Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate inhalers for chronic obstructive pulmonary diseases such as asthma. Such substantial investments to address the medical needs of the rising patient pool are expected to elevate the market value.
The increased initiatives and campaigns to raise awareness about respiratory diseases and their management are poised to positively influence the Asia Pacific respiratory inhalers market share. For instance, in May 2023, an Indian multinational pharmaceutical company Alkem Laboratories Limited announced its 'Reliever Free India' initiative to raise awareness about asthma and the hazards of over-usage of reliever medication. The campaign promotes the use of SMART therapy which requires only one inhaler for daily and reliever asthma treatment. The rise of such initiatives coupled with the increasing healthcare expenditure in the region is expected to bolster market growth.
Asia Pacific Respiratory Inhalers Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product Type | Dry Powdered Inhalers (Multi-Dose Dry Powder Inhalers, Single Dose Dry Powder Inhalers), Metered Dose Inhalers (Pressured Metered Dose Inhalers, Connected Metered Dose Inhalers), Nebulizers (Compressed Air Nebulizers, Mesh Air Nebulizers, Ultrasonic Air Nebulizers), Others |
| Technology | Manually Operated Inhaler, Digitally Operated Inhaler |
| Indication | Asthma, COPD, Pulmonary Arterial Hypertension, Others Respiratory Disease |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies and Online Pharmacies |
| End User | Hospitals and Clinics, Homecare Settings, Respiratory Care Centers |
| Countries | China, Japan, ASEAN, Australia, India, Others |
Asia Pacific Respiratory Inhalers Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AstraZeneca Plc
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd
- GSK Plc
- Koninklijke Philips NV
- OMRON Corp
- PARI Respiratory Equipment, Inc.
- OPKO Health, Inc
- Teva Pharmaceutical Industries Ltd
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Technology |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific Respiratory Inhalers Market Overview
3.1 Asia Pacific Respiratory Inhalers Market Historical Value (2017-2023)
3.2 Asia Pacific Respiratory Inhalers Market Forecast Value (2024-2032)
4 Asia Pacific Respiratory Inhalers Market Landscape*
4.1 Asia Pacific Respiratory Inhalers Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific Respiratory Inhalers Market: Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Material
4.2.3 Analysis by Type
5 Asia Pacific Respiratory Inhalers Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific Respiratory Inhalers Market Segmentation (2017-2032)
6.1 Asia Pacific Respiratory Inhalers Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Dry Powdered Inhalers
6.1.2.1 Multi-Dose Dry Powder Inhalers
6.1.2.2 Single Dose Dry Powder Inhalers
6.1.3 Metered Dose Inhalers
6.1.3.1 Pressured Metered Dose Inhalers
6.1.3.2 Connected Metered Dose Inhalers
6.1.4 Nebulizers
6.1.4.1 Compressed Air Nebulizers
6.1.4.2 Mesh Air Nebulizers
6.1.4.3 Ultrasonic Air Nebulizers
6.1.5 Others
6.2 Asia Pacific Respiratory Inhalers Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Manually Operated Inhaler
6.2.3 Digitally Operated Inhaler
6.3 Asia Pacific Respiratory Inhalers Market (2017-2032) by Indication
6.3.1 Market Overview
6.3.2 Asthma
6.3.3 COPD
6.3.4 Pulmonary Arterial Hypertension
6.3.5 Others Respiratory Disease
6.4 Asia Pacific Respiratory Inhalers Market (2017-2032) by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacies
6.4.3 Retail Pharmacies
6.4.4 Online Pharmacies
6.5 Asia Pacific Respiratory Inhalers Market (2017-2032) by End User
6.5.1 Market Overview
6.5.2 Hospitals & Clinics
6.5.3 Homecare Settings
6.5.4 Respiratory Care Centers
6.6 Asia Pacific Respiratory Inhalers Market (2017-2032) by Countries
6.6.1 Market Overview
6.6.2 China
6.6.3 Japan
6.6.4 ASEAN
6.6.5 Australia
6.6.6 India
6.6.7 Others
7 China Respiratory Inhalers Market (2017-2032)
7.1 China Respiratory Inhalers Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Dry Powdered Inhalers
7.1.2.1 Multi-Dose Dry Powder Inhalers
7.1.2.2 Single Dose Dry Powder Inhalers
7.1.3 Metered Dose Inhalers
7.1.3.1 Pressured Metered Dose Inhalers
7.1.3.2 Connected Metered Dose Inhalers
7.1.4 Nebulizers
7.1.4.1 Compressed Air Nebulizers
7.1.4.2 Mesh Air Nebulizers
7.1.4.3 Ultrasonic Air Nebulizers
7.1.5 Others
7.2 China Respiratory Inhalers Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Manually Operated Inhaler
7.2.3 Digitally Operated Inhaler
7.3 China Respiratory Inhalers Market (2017-2032) by Indication
7.3.1 Market Overview
7.3.2 Asthma
7.3.3 COPD
7.3.4 Pulmonary Arterial Hypertension
7.3.5 Others Respiratory Disease
7.4 China Respiratory Inhalers Market (2017-2032) by Distribution Channel
7.4.1 Market Overview
7.4.2 Hospital Pharmacies
7.4.3 Retail Pharmacies
7.4.4 Online Pharmacies
7.5 China Inhalers Market (2017-2032) by End User
7.5.1 Market Overview
7.5.2 Hospitals & Clinics
7.5.3 Homecare Settings
7.5.4 Respiratory Care Centers
8 Japan Respiratory Inhalers Market (2017-2032)
8.1 Japan Respiratory Inhalers Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Dry Powdered Inhalers
8.1.2.1 Multi-Dose Dry Powder Inhalers
8.1.2.2 Single Dose Dry Powder Inhalers
8.1.3 Metered Dose Inhalers
8.1.3.1 Pressured Metered Dose Inhalers
8.1.3.2 Connected Metered Dose Inhalers
8.1.4 Nebulizers
8.1.4.1 Compressed Air Nebulizers
8.1.4.2 Mesh Air Nebulizers
8.1.4.3 Ultrasonic Air Nebulizers
8.1.5 Others
8.2 Japan Respiratory Inhalers Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Manually Operated Inhaler
8.2.3 Digitally Operated Inhaler
8.3 Japan Respiratory Inhalers Market (2017-2032) by Indication
8.3.1 Market Overview
8.3.2 Asthma
8.3.3 COPD
8.3.4 Pulmonary Arterial Hypertension
8.3.5 Others Respiratory Disease
8.4 Japan Respiratory Inhalers Market (2017-2032) by Distribution Channel
8.4.1 Market Overview
8.4.2 Hospital Pharmacies
8.4.3 Retail Pharmacies
8.4.4 Online Pharmacies
8.5 Japan Respiratory Inhalers Market (2017-2032) by End User
8.5.1 Market Overview
8.5.2 Hospitals & Clinics
8.5.3 Homecare Settings
8.5.4 Respiratory Care Centers
9 ASEAN Respiratory Inhalers Market (2017-2032)
9.1 ASEAN Respiratory Inhalers Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Dry Powdered Inhalers
9.1.2.1 Multi-Dose Dry Powder Inhalers
9.1.2.2 Single Dose Dry Powder Inhalers
9.1.3 Metered Dose Inhalers
9.1.3.1 Pressured Metered Dose Inhalers
9.1.3.2 Connected Metered Dose Inhalers
9.1.4 Nebulizers
9.1.4.1 Compressed Air Nebulizers
9.1.4.2 Mesh Air Nebulizers
9.1.4.3 Ultrasonic Air Nebulizers
9.1.5 Others
9.2 ASEAN Respiratory Inhalers Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Manually Operated Inhaler
9.2.3 Digitally Operated Inhaler
9.3 ASEAN Respiratory Inhalers Market (2017-2032) by Indication
9.3.1 Market Overview
9.3.2 Asthma
9.3.3 COPD
9.3.4 Pulmonary Arterial Hypertension
9.3.5 Others Respiratory Disease
9.4 ASEAN Respiratory Inhalers Market (2017-2032) by Distribution Channel
9.4.1 Market Overview
9.4.2 Hospital Pharmacies
9.4.3 Retail Pharmacies
9.4.4 Online Pharmacies
9.5 ASEAN Respiratory Inhalers Market (2017-2032) by End User
9.5.1 Market Overview
9.5.2 Hospitals & Clinics
9.5.3 Homecare Settings
9.5.4 Respiratory Care Centers
10 Australia Respiratory Inhalers Market (2017-2032)
10.1 Australia Respiratory Inhalers Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Dry Powdered Inhalers
10.1.2.1 Multi-Dose Dry Powder Inhalers
10.1.2.2 Single Dose Dry Powder Inhalers
10.1.3 Metered Dose Inhalers
10.1.3.1 Pressured Metered Dose Inhalers
10.1.3.2 Connected Metered Dose Inhalers
10.1.4 Nebulizers
10.1.4.1 Compressed Air Nebulizers
10.1.4.2 Mesh Air Nebulizers
10.1.4.3 Ultrasonic Air Nebulizers
10.1.5 Others
10.2 Australia Respiratory Inhalers Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Manually Operated Inhaler
10.2.3 Digitally Operated Inhaler
10.3 Australia Respiratory Inhalers Market (2017-2032) by Indication
10.3.1 Market Overview
10.3.2 Asthma
10.3.3 COPD
10.3.4 Pulmonary Arterial Hypertension
10.3.5 Others Respiratory Disease
10.4 Australia Respiratory Inhalers Market (2017-2032) by Distribution Channel
10.4.1 Market Overview
10.4.2 Hospital Pharmacies
10.4.3 Retail Pharmacies & Online Pharmacies
10.5 Australia Respiratory Inhalers Market (2017-2032) by End User
10.5.1 Market Overview
10.5.2 Hospitals & Clinics
10.5.3 Homecare Settings
10.5.4 Respiratory Care Centers
11 India Respiratory Inhalers Market (2017-2032)
11.1 India Respiratory Inhalers Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Dry Powdered Inhalers
11.1.2.1 Multi-Dose Dry Powder Inhalers
11.1.2.2 Single Dose Dry Powder Inhalers
11.1.3 Metered Dose Inhalers
11.1.3.1 Pressured Metered Dose Inhalers
11.1.3.2 Connected Metered Dose Inhalers
11.1.4 Nebulizers
11.1.4.1 Compressed Air Nebulizers
11.1.4.2 Mesh Air Nebulizers
11.1.4.3 Ultrasonic Air Nebulizers
11.1.5 Others
11.2 India Respiratory Inhalers Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Manually Operated Inhaler
11.2.3 Digitally Operated Inhaler
11.3 India Respiratory Inhalers Market (2017-2032) by Indication
11.3.1 Market Overview
11.3.2 Asthma
11.3.3 COPD
11.3.4 Pulmonary Arterial Hypertension
11.3.5 Others Respiratory Disease
11.4 India Respiratory Inhalers Market (2017-2032) by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Retail Pharmacies
11.4.4 Online Pharmacies
11.5 India Respiratory Inhalers Market (2017-2032) by End User
11.5.1 Market Overview
11.5.2 Hospitals & Clinics
11.5.3 Homecare Settings
11.5.4 Respiratory Care Centers
12 Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 AstraZeneca Plc
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Beximco Pharmaceuticals Ltd.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Boehringer Ingelheim International GmbH
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Cipla Ltd
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 GSK Plc
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Koninklijke Philips NV
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 OMRON Corp
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 PARI Respiratory Equipment, In
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 OPKO Health, Inc
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Teva Pharmaceutical Industries Ltd
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 Asia Pacific Respiratory Inhalers Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Asia Pacific respiratory inhalers market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 53.9 billion by 2032.
The rising demand for digitally operated and smart inhaler technologies is fuelling the demand for the market.
One of the significant trends in the market is the increased investment in the respiratory inhaler segment by the key market players. In August 2023 , AstraZeneca invested an additional amount of USD 250 million in its asthma inhaler plant in China’s Qingdao, with the total investment in the factory reported to be USD 700 million.
Based on the product type, the market is segmented into dry powdered inhalers (multi-dose dry powder inhalers, single dose dry powder inhalers), metered dose inhalers (pressured metered dose inhalers, connected metered dose inhalers), and nebulizers (compressed air nebulizers, mesh air nebulizers, ultrasonic air nebulizers), among others.
By technology, the market is divided into manually operated inhalers and digitally operated inhalers.
By indication, the market includes asthma, COPD, and pulmonary arterial hypertension, among other respiratory diseases.
By end use, the market is segmented into hospitals & clinics, homecare settings, and respiratory care centers.
Major distribution channels of the market include hospital pharmacies, retail pharmacies and online pharmacies.
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.
The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc., OPKO Health, Inc., and Teva Pharmaceutical Industries Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER